New bioactive material regenerates high-quality cartilage in the knee joints of large-animal model

Experts from industry and academia and lawmakers reached consensus around the dangers and the drivers of drug shortages but clashed over approaches to solving the

Be­gin­ning lat­er this month, Pfiz­er is launch­ing an in­ter­change­able biosim­i­lar to Ab­b­Vie’s block­buster rheuma­toid arthri­tis drug Hu­mi­ra (adal­i­mum­ab) at a 5% dis­count on the whole­sale